SpringWorks Therapeutics Inc (SWTX) concluded trading on Thursday at a closing price of $59.93, with 5.14 million shares of worth about $307.99 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 62.15% during that period and on February 20, 2025 the price saw a gain of about 7.54%. Currently the company’s common shares owned by public are about 74.39M shares, out of which, 65.39M shares are available for trading.
Stock saw a price change of 1.10% in past 5 days and over the past one month there was a price change of 64.87%. Year-to-date (YTD), SWTX shares are showing a performance of 65.87% which increased to 14.41% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $28.21 but also hit the highest price of $60.00 during that period. The average intraday trading volume for SpringWorks Therapeutics Inc shares is 1.88 million. The stock is currently trading 32.23% above its 20-day simple moving average (SMA20), while that difference is up 47.40% for SMA50 and it goes to 57.63% higher than SMA200.
SpringWorks Therapeutics Inc (NASDAQ: SWTX) currently have 74.39M outstanding shares and institutions hold larger chunk of about 105.87% of that.
The stock has a current market capitalization of $4.46B and its 3Y-monthly beta is at 0.86. It has posted earnings per share of -$3.48 in the same period. It has Quick Ratio of 6.02 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for SWTX, volatility over the week remained 4.43% while standing at 8.04% over the month.
Stock’s fiscal year EPS is expected to rise by 39.37% while it is estimated to increase by 73.93% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Evercore ISI on November 20, 2024 offering an Outperform rating for the stock and assigned a target price of $60 to it. Coverage by Guggenheim stated SpringWorks Therapeutics Inc (SWTX) stock as a Buy in their note to investors on February 05, 2024, suggesting a price target of $75 for the stock. On December 01, 2022, BofA Securities Initiated their recommendations, while on January 19, 2021, H.C. Wainwright Reiterated their ratings for the stock with a price target of $101. Stock get a Buy rating from H.C. Wainwright on October 29, 2020.
